NCT06342349View on ClinicalTrials.gov

A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above.

PHASE1CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

March 30, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Influenza
Interventions
BIOLOGICAL

Quadrivalent influenza virus split vaccine (MDCK cells)

Quadrivalent influenza vaccine made from cell matrix (0.5ml/dose).

BIOLOGICAL

Quadrivalent influenza virus split vaccine (Chicken embryo)

Quadrivalent influenza vaccine made from chicken embryo(0.5ml/dose).

OTHER

Phosphate buffer solution

Phosphate buffer solution without vaccine antigen(0.5ml/dose).

Trial Locations (1)

Unknown

Shanxi Provincial Center for Disease Prevention and Control, Shanxi

All Listed Sponsors
collaborator

Shaanxi Provincial Center for Disease Control and Prevention

OTHER

lead

Shanghai Institute Of Biological Products

INDUSTRY

NCT06342349 - A Clinical Trial of Quadrivalent Influenza Virus Split Vaccine (MDCK Cells) for Individuals Aged 6 Months and Above. | Biotech Hunter | Biotech Hunter